Triomics has closed a $22 million Series B funding round led by Battery Ventures. The oncology AI startup builds machine learning tools designed specifically for cancer centers to improve diagnostic accuracy and treatment planning.
The funding positions Triomics to expand its platform across more hospital systems and oncology practices. Cancer diagnosis and treatment planning remain labor-intensive processes where AI can reduce errors and accelerate clinical decision-making. Triomics focuses on building models trained on oncology-specific data rather than generic medical AI systems that may not perform well on cancer pathology cases.
Battery Ventures leads the round, signaling confidence in Triomics' approach to vertical AI within healthcare. The firm has backed multiple healthtech companies targeting specific medical domains. Earlier backers likely participated in this round as well.
Triomics competes in a crowded space where multiple startups pursue AI for oncology. Companies like Paige, Tempus, and others have raised substantial capital for cancer AI applications. Triomics differentiates by focusing deeply on cancer center workflows rather than building broader diagnostic or research platforms.
The $22 million injection allows the startup to invest in product development, clinical validation, and go-to-market efforts. Cancer centers face pressure to improve outcomes while managing rising costs. AI tools that integrate into existing workflows and demonstrably improve diagnostic accuracy command high adoption potential. Regulatory clearances, clinical evidence, and integration with hospital information systems remain critical hurdles for oncology AI companies.
With this capital, Triomics can accelerate hiring in engineering, clinical operations, and sales teams focused on cancer institutions. The startup likely targets large academic medical centers and regional cancer networks where centralized purchasing decisions and research partnerships create expansion opportunities. Battery Ventures' network in healthcare may also open doors to hospital system partnerships and potential follow-on funding rounds.